Meeting
2021 Genitourinary Cancers Symposium
Concomitant antibiotics (ATBs) use and survival outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab (PURE-01 study).
Authors
Daniele Raggi
IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy
Daniele Raggi , Marco Bandini , Filippo Pederzoli , Patrizia Giannatempo , Laura Marandino , Giuseppe Basile , Andrea Gallina , Alberto Briganti , Francesco Montorsi , Andrea Necchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02736266
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 449)
DOI
10.1200/JCO.2021.39.6_suppl.449
Abstract #
449
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer.
First Author: Michael Lattanzi
Poster
2021 ASCO Annual Meeting
Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.
First Author: Filippo Pederzoli
Poster
2020 Genitourinary Cancers Symposium
Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC).
First Author: Andrea Necchi
Poster
2018 ASCO Annual Meeting
Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).
First Author: Megan Greally